Race affects access to nephrectomy but not survival in renal cell carcinoma

BJU International

Volumn 103, Issue 7, 2009, Pages 889-893

  Zini, Laurent ^a,c   Perrotte, Paul ^b   Capitanio, Umberto ^a,e   Jeldres, Claudio ^a   Duclos, Alain ^b   Arjane, Philippe ^b   Villers, Arnauld ^c   Montorsi, Francesco ^e   Patard, Jean Jacques ^d   Karakiewicz, Pierre I ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Access to care; Nephrectomy; Race; Renal cancer; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CARCINOMA, RENAL CELL; EPIDEMIOLOGIC METHODS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 62149127674     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08119.x     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 : 106 30
2. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007 51 : 1502 10
3. Antonelli A, Cozzoli A, Nicolai M et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm. Eur Urol 2008 53 : 803 9
4. Karakiewicz PI, Trinh QD, Bhojani N et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007 51 : 1616 24
5. Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006 49 : 633 43
6. Berndt SI, Carter HB, Schoenberg MP, Newschaffer CJ. Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol 2007 25 : 3589 95
7. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD : National Cancer Institute, 2007. Available at: http://seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site. Accessed January 2007
8. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 2002 40 : IV 19-25
9. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 2008 112 : 1480 8
10. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003 157 : 940 3
11. Vaishampayan UN, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 2003 62 : 1012 7
12. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment. Cancer 2003 97 : 2853 60
13. Govindarajan R, Shah RV, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. Cancer 2003 97 : 493 8
14. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999 341 : 1198 205
15. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
16. Motzer RJ, Rakhit A, Thompson J et al. Phase II trial of branched peg interferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002 13 : 1799 805
17. Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007 110 : 1241 7
18. Karakiewicz PI, Trinh QD, de la Taille A et al. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. Eur J Cancer 2007 43 : 1023 9